RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TL;DR
Dr. Zamore's appointment enhances TransCode's RNA-targeted cancer therapy programs, giving a strategic edge in the field.
TransCode focuses on treating metastatic disease through intelligent RNA therapeutics delivery with TTX nanoparticle platform.
TransCode's innovative RNA therapeutics offer hope for better cancer treatment by targeting specific genetic markers of metastatic tumors.
Dr. Zamore's foundational work in RNA biology adds a fascinating dimension to TransCode's cutting-edge cancer therapy research.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics has strategically enhanced its scientific capabilities by appointing Dr. Phillip D. Zamore to its Scientific Advisory Board. Zamore, a leading expert in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, brings significant expertise to the clinical-stage oncology company.
As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Zamore is recognized for groundbreaking work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences underscores his substantial contributions to the field of genetic research.
TransCode is developing RNA therapeutics targeting metastatic cancers, with its lead candidate TTX-MC138 focusing on tumors overexpressing microRNA-10b. Zamore's appointment signals potential acceleration and validation of the company's innovative RNA-targeted cancer therapy programs.
The addition of such a prominent scientific figure could provide TransCode with critical insights into RNA therapeutic development, potentially improving the company's approach to treating complex metastatic diseases. Zamore's expertise may help refine TransCode's proprietary TTX nanoparticle platform and advance its portfolio of RNA therapeutic candidates.
Curated from InvestorBrandNetwork (IBN)
